Início › Insuficiência Cardíaca › Washington › Seattle
Ensaios clínicos de Insuficiência Cardíaca em Seattle, WA
17 estudos para Insuficiência Cardíaca estão buscando participantes em locais em Seattle e arredores (num raio de aproximadamente 30 milhas). Abra um estudo para ver quem pode participar e como contatar a equipe.
Texto oficial do estudo (Inglês)
Recrutando participantes para um estudo? Destaque-o no topo desta página — $99 por 30 dias →
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
RecrutandoFase 3
- Virginia Mason Medical Center, Seattle
A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)
RecrutandoFase 2
- Local Institution - 132, Seattle
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
RecrutandoFase 2/3
- Seattle Children's Hospital-Cardiology/Fetal Therapy ( Site 0019), Seattle
AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF
RecrutandoFase 2
- Swedish Heart & Vascular Institute, Advanced Cardiac Support Program, Seattle
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
RecrutandoEstudo observacional
- Virginia Mason Medical Center, Seattle
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
RecrutandoFase 3
- Tenax Investigational Site, Seattle
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
RecrutandoFase 3
- Swedish Medical Center_Seattle, Seattle
Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System
RecrutandoFase 2
- Seattle Children's Hospital, Seattle
Assessment of CCM in HF With Higher Ejection Fraction
Recrutando
- Swedish Medical Center, Seattle
Repurposing Valsartan May Protect Against Pulmonary Hypertension
RecrutandoFase 2
- University of Washington Medical Center, Seattle
Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease
RecrutandoFase 3
- University of Washington, Seattle
XVIVO Heart Box (XHB) With Supplemented XVIVO Heart Solution (SXHS) Continued Access Protocol (CAP)
Recrutando
- University of Washington Medical Center, Seattle
Proof-of-concept of a Behavioral Intervention to Improve the Cardiovascular Health of People Living With HIV
Recrutando
- University of Washington, Seattle
Left vs Left Randomized Clinical Trial
Recrutando
- University of Washington, Seattle
Cardiogenic Shock Working Group Registry
RecrutandoEstudo observacional
- University of Washington Medical Center, Seattle
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
RecrutandoFase 1/2
- University of Washington Medicine, Seattle
Study of the Clinical Impact of Surgical Correction of Tricuspid Insufficiency in Implantable LVAD Patients
Recrutando
- University of Washington Medical Center, Seattle
Ensaios de Insuficiência Cardíaca em outras cidades
- New York City, NY51 estudos
- Boston, MA44 estudos
- Dallas, TX42 estudos
- Houston, TX36 estudos
- Cleveland, OH33 estudos
- Philadelphia, PA31 estudos
- Chicago, IL31 estudos
- San Francisco, CA29 estudos
- St. Louis, MO26 estudos
- Durham, NC26 estudos
- Kansas City, MO25 estudos
- Atlanta, GA25 estudos
Outros estudos em Seattle
- Câncer de Pulmão de Não Pequenas Células53 estudos
- Câncer (todos os tipos)49 estudos
- Câncer de Próstata44 estudos
- Leucemia Mieloide Aguda40 estudos
- Câncer de Mama40 estudos
- Câncer Metastático39 estudos
- Câncer Colorretal34 estudos
- Câncer de Pulmão33 estudos
- Câncer de Ovário31 estudos
- Mieloma Múltiplo22 estudos
- Câncer de Pâncreas22 estudos
- Câncer de Bexiga21 estudos
Fonte: ClinicalTrials.gov, dados obtidos em 2 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.